UBT251: selling the world to Novo Nordisk and keeping China for itself — The United Laboratories' "atypical" way of going global

To understand UBT251, first understand the underlying character of United Laboratories. It is not a biotech kept alive by financing and betting on a single product, but a large Chinese pharma company with a complete industrial chain and stable cash flow. In 2024 the company had revenue of RMB 13.759 billion — intermediates RMB 2.659 billion, APIs RMB 6.373 billion and finished formulations RMB 4.728 billion — and net profit attributable to shareholders of about RMB 2.66 billion. With about 17,000 employees, its businesses span three segments: the full antibiotic industrial chain, animal health and diabetes.

The key trump card: the insulin commercial platform. In 2024 the company's diabetes product revenue was about RMB 1.248 billion, up 9.5% year on year, and insulin analogue volume rose 17.2%. In the 2024 renewal of the national insulin volume-based procurement, the group's entire insulin line won bids as Category A, with the procurement base volume up sharply by 52.5%. This means United Laboratories already has an organized, battle-ready commercial team in endocrinology and chronic disease management.

This team is the foundation of UBT251's China story. A triple-agonist weight-loss/glucose-lowering molecule needs to reach exactly endocrinology departments and metabolic clinics — which overlap heavily with the target departments for United Laboratories' insulin. In other words, when another domestic biotech gets a weight-loss molecule it has to build a commercial team from zero; United Laboratories has what amounts to "ready-made channels waiting for new ammunition".

UBT251 itself is a long-acting synthetic peptide injected subcutaneously once a week, with one molecule simultaneously activating three incretin/energy metabolism pathways: GLP-1 and GIP suppress appetite and control blood glucose, while GCG (glucagon) raises energy expenditure and promotes hepatic fat breakdown. This "three-pronged" mechanism has been validated globally by Lilly's same-class molecule retatrutide as the lane with the highest ceiling for weight-loss efficacy.

Why would a "metabolic veteran" go all in on obesity? Because it is standing on the biggest blue ocean in Chinese pharma over the past decade. According to the National Health Commission's 2024 weight management guidelines, more than 50% of Chinese adults are overweight or obese (overweight 34.3% and obesity 16.4% in 2018, 50.7% combined), about 500 million people or more; there are about 140 million people with diabetes. The Chinese market for GLP-1 weight-loss drugs is widely expected to exceed RMB 150 billion, with treatment penetration expected to rise from under 5% in 2023 to 18%–20%. A molecule with a mechanistic barrier, its own commercial platform and a position in a super-lane is for United Laboratories not just a product, but an opportunity to reshape its identity — leaping from "API and insulin supplier" to "metabolic innovative drug company".

Whether an early license gets done ultimately depends on data. The two key readouts UBT251 produced in China are the real "price tag" of this deal.

Weight loss: in a randomized double-blind placebo-controlled study of 205 Chinese people with overweight/obesity (mean baseline weight 92.2 kg, mean BMI 33.1), once-weekly doses of 2 mg, 4 mg and 6 mg for 24 weeks:

All dose arms reached statistically significant differences versus placebo, and the weight-loss curve had not yet plateaued at 24 weeks — meaning there is still room to go lower with longer treatment. For reference, in an earlier Phase 1b study the 6 mg arm had already lost 15.1% at 12 weeks. Achieving close to 20% weight loss in a short period puts it in the first tier of domestic weight-loss assets.

Glucose-lowering: another study of 211 Chinese patients with type 2 diabetes is even more notable — it directly included a head-to-head semaglutide 1 mg arm (baseline HbA1c 8.12%):

On both glucose control and weight loss, UBT251 outperformed semaglutide 1 mg, the globally recognized yardstick. On safety, the most common adverse reactions were gastrointestinal, mostly mild to moderate and easing over time — consistent with the incretin class. It was precisely such a set of "deep, fast and head-to-head superior" curves that made a global obesity leader like Novo Nordisk willing to place a bet at an early stage.

This also defines UBT251's global "exam syllabus": the question it has to answer is not "can it cause weight loss" — the mechanism and early data have already answered yes; but "over the long run of 70+ weeks, in Western populations, and in head-on contests with tirzepatide and even retatrutide, can it hold first-tier efficacy with acceptable tolerability". United Laboratories cannot answer this question itself; it depends on Novo Nordisk answering it through global Phase 2/3 (the currently registered study is a US/Canada Phase 2 of about 333 planned patients, starting in early 2026). For United Laboratories, this is both the wisdom of outsourcing uncertainty and the helplessness of putting its fate in someone else's hands — how much of the US$1.8 billion in global milestones is realized depends almost entirely on the score of this exam.

Greater China is the main battlefield United Laboratories kept for itself, and the registration path has been laid out. The China weight-loss Phase 3 registration study has been registered but has not yet started recruiting: it plans to enroll 600 people with overweight/obesity, with 4 mg and 6 mg doses versus placebo, randomized and triple-blind, with percentage change in body weight from baseline at 52 weeks as the primary endpoint, led by top centers such as Peking University People's Hospital; it is expected to start at the end of July 2026, complete the primary analysis at the end of September 2027, and complete overall in early November 2027. At this pace, UBT251 would launch in China around 2028. In addition, chronic kidney disease (Phase 2 recruiting, 180 planned patients, primary completion expected mid-2030) and metabolic dysfunction-associated steatohepatitis, MASH (Phase 2 recruiting, 156 planned patients, primary completion expected mid-2027) are also advancing.

The biggest practical pressure is "arriving late". Semaglutide and tirzepatide weight-loss indications were approved in China in 2024 and launched in early 2025; Innovent's mazdutide (a GLP-1/GCG dual agonist, the world's first GCG/GLP-1 dual receptor agonist approved for weight management) was approved by the NMPA in June 2025, and its higher 9 mg dose has read out about −18.55% weight loss at 60 weeks, pushing competitive pressure up further. That is, when UBT251 reaches the finish line around 2028, at least three weight-loss drugs will be 3–4 years ahead of it on the track, and Lilly's triple agonist retatrutide is also already running clinical trials in China. First movers' brands, hospital access and price wars are all barriers a latecomer has to force its way through.

The card United Laboratories can play is "trading depth of efficacy for launch timing" — if Phase 3 can consistently reproduce weight loss close to 20% or deeper, combined with its glucose-control advantage, UBT251 can still carve out differentiated space in high-BMI populations with metabolic comorbidities. The precondition: the long-term safety database must be filled out (especially long-term signals such as heart rate and blood glucose related to the GCG component), and expedited review must be actively pursued rather than assumed.

What peers in China should study most about the UBT251 deal is its rights structure design. It neither sold global rights outright for a lump sum nor stubbornly tried to go global alone — instead it made a clean "cut".

① Hand the world to the most suitable party. Global development of weight-loss drugs is an "arms race" of money, clinical networks and commercial brands, with thresholds so high that domestic pharma companies can hardly cross them alone. United Laboratories chose to license all rights outside Greater China to a single partner, Novo Nordisk — rather than splitting by region among several. This matters: a single partner avoids the common aftereffects of "multiple sublicenses" such as label fragmentation, brand splits and complicated royalty allocation. Novo Nordisk holds the global Wegovy/Ozempic weight-loss commercial network and has already started an international multicenter Phase 2 of UBT251 in the US and Canada (about 333 planned patients). One could say United Laboratories handed the global baton to the strongest relay runner in the race.

Look at it from the other side — why was Novo Nordisk willing to take it? As the pioneer of the GLP-1 era, it is being pressed step by step by Lilly's tirzepatide and the higher-order triple agonist retatrutide, and its ammunition for the next generation of "deeper weight loss" is not plentiful. In-licensing a triple agonist that has already produced close to 20% weight loss in China and is head-to-head superior on glucose control is, for Novo Nordisk, a low-upfront, high-potential bet to "reinforce the next-generation pipeline". Buyer and seller each got what they needed — that is the underlying logic of why this deal could close at an early stage: United Laboratories wanted global capability and endorsement, Novo Nordisk wanted a differentiated next-generation asset.

② Keep China firmly in hand. Unlike "selling the world outright", United Laboratories resolutely kept Greater China. The reason is exactly the insulin commercial team discussed in Section 1: in China it does not need to build a commercial system for UBT251 from scratch — hospital access pathways, formulary committee experience and sales teams in endocrinology and chronic disease management are all in place. Even better, United Laboratories is also advancing its own semaglutide biosimilar — it was one of the first companies in China to obtain clinical trial approval for the weight management indication of this biosimilar; the diabetes indication has entered the marketing application (NDA) stage and the weight management indication has advanced to Phase 3. This means United Laboratories can build a metabolic product ladder in China of "insulin → semaglutide biosimilar → UBT251 triple agonist", using the same team and the same customers to amplify single-product return on investment layer by layer.

This ladder also hides a clever timing design. UBT251 won't launch in China until around 2028 — what about the years in between? The answer is the semaglutide biosimilar. As the originator's core compound patent nears expiry, domestic semaglutide biosimilars are expected to scale first — letting United Laboratories' weight-loss commercial team "warm up" early and thoroughly work channels and market education, while also taking a share of the weight-loss market before UBT251 arrives. When the triple-agonist flagship finally takes the stage, United Laboratories will face not a rusty team and an unfamiliar market, but a mature, well-run pathway ready to be loaded with "stronger ammunition". Use biosimilars to nurture the channel, use innovative drugs to harvest the high end — a road only "portfolio-type" large pharma can walk; single-product biotechs cannot copy it.

The game in one sentence: the global rights bought "certain cash + endorsement by a top partner + a royalty option on global upside"; keeping Greater China bought "a home turf that can generate cash independently using a ready-made commercial platform". The former de-risks, the latter preserves upside — precisely where large Chinese pharma companies are more at ease than single-product biotechs when globalizing.

Now that the price war in weight-loss drugs has begun (tirzepatide's price in China was at one point cut by about 80%, and semaglutide's core compound patent is nearing expiry), cost capability is becoming a hidden decisive factor. This is exactly United Laboratories' strength. As one of China's largest antibiotic API and intermediate companies, it has deep experience in API integration, large-scale synthesis and global GMP supply. Scale-up of a long-acting triple-agonist peptide and commercial batch process consistency still need to be validated at the Phase 3 stage, but United Laboratories has already built peptide capacity in Zhuhai Hengqin, and together with the cost control of API integration, this gives it more confidence than pure R&D biotechs to "withstand price cuts" in future price wars.

The links that need strengthening are also clear: once-weekly subcutaneous injection needs a friendly pen/prefilled device to improve adherence, and the experience must not fall behind already-marketed pen competitors; aggregates and immunogenicity of a long peptide also need continued monitoring in larger samples.

In United Laboratories' map, UBT251 is a flag — representing this "API + generics" veteran's landmark achievement in its transition to innovative drugs, the asset publicly endorsed by management with the highest resource priority. Remarkably, it barely conflicts with existing businesses: insulin provides cash flow and channels, the semaglutide biosimilar provides same-platform peptide capacity and a weight-loss market entry point, and UBT251 is the "apex" of the portfolio. Novo Nordisk's US$200 million upfront also provides non-dilutive ammunition for further investment. A flagship with no shortage of funds, ready-made channels and synergy with the core business has a very low opportunity cost.

But a flagship carries flagship risk: high visibility means a high cost of failure. If the China Phase 3 falls short, the blow would land not only on one product but on the whole "innovation transformation" narrative and the valuation it supports. This requires United Laboratories, while enjoying the flagship's halo, to keep portfolio discipline — clear termination/downgrade triggers, avoiding soldiering on under sunk costs.

Viewed across the whole industry, the UBT251 deal represents a paradigm of Chinese innovative drugs going global that is maturing. In earlier years, domestic assets going abroad were often "passive outright sales" — how much money and what terms were mostly the buyer's call. This deal, by contrast, was negotiated with its own commercial platform and a clear home-turf strategy: knowing it could make the product succeed in China on its own, United Laboratories only put "the global part it cannot do itself" on the table, and insisted on keeping Greater China, where it is most confident. This structure of "home turf as the anchor, the world as an option" gave a domestic pharma company, for the first time, the confidence at the BD table of "neither selling cheap nor overreaching".

The UBT251 story is a mature sample of Chinese innovative drugs going global: when you hold a good molecule recognized in a globally validated lane, and have a commercial team that can generate cash independently at home, the optimal solution is not necessarily "sell everything" or "keep everything", but to hand global uncertainty to the strongest partner to digest, and keep Chinese certainty for yourself to realize. With one "atypical" way of going global, United Laboratories turned "selling green shoots" into a three-way win of "cash, home turf and a global option".

The open questions are also clear: it has arrived too late in the Chinese market, and it has no say over global value. Over the next three years, whether Phase 3 data can reproduce that not-yet-plateaued weight-loss curve, and how far Novo Nordisk pushes the molecule, will together determine whether this US$2 billion deal was ultimately a shrewd cash-out, or the starting point of a veteran pharma company's true transformation.